SPTLC1 variants associated with early‐onset ALS are postulated to enhance SPT activity by interfering with the binding of mutant SPT to ORMDL3, promoting the overproduction of sphingolipids, thereby leading to ALS manifestation.10, 39. The gene discussed is AGXT; the disease is amyotrophic lateral sclerosis.